Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.48 |
| ▸ | HTR2B | P41595 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13263366 | 1.00 | HTR2C (0.48) | HTR2CHTR2BALDH1A1PKMCYP3A4 | |
| SCHEMBL15386481 | 1.00 | HTR2C (0.48) | HTR2CHTR2BALDH1A1PKMCYP3A4 | |
| SCHEMBL12344001 | 0.90 | DPP4 (0.45) | HTR2CHTR2BALDH1A1PKMCYP3A4 | |
| SCHEMBL8535634 | 0.87 | ALDH1A1 (0.59) | HTR2CHTR2BALDH1A1PKMCYP3A4 | |
| SCHEMBL8393443 | 0.87 | ALDH1A1 (0.59) | HTR2CHTR2BALDH1A1PKMCYP3A4 | |
| SCHEMBL30179363 | 0.87 | ALDH1A1 (0.59) | HTR2CHTR2BALDH1A1PKMCYP3A4 | |
| Hydrochloric Acid SCHEMBL9275339 | 0.86 | POLB (0.57) | HTR2CHTR2BALDH1A1PKMCYP3A4 | |
| Hydrochloric Acid SCHEMBL9275345 | 0.86 | POLB (0.57) | HTR2CHTR2BALDH1A1PKMCYP3A4 | |
| Hydrochloric Acid SCHEMBL27541627 | 0.86 | ALDH1A1 (0.58) | HTR2CHTR2BALDH1A1PKMCYP3A4 | |
| Glycine SCHEMBL28382745 | 0.82 | ALDH1A1 (0.54) | HTR2CHTR2BALDH1A1PKMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-08-10 | — | — | US | disclosed |
| US-9629921-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629921-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-04-25 | — | — | US | disclosed |
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | BACH BIOSCIENCES, LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | BACH BIOSCIENCES, LLC | 2013-11-14 | — | — | US | disclosed |
| EP-2319523-A1 | Serine protease inhibitors | Trustees Of Tufts College (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2204181-A2 | Protease inhibitors | Trustees of Tufts College (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-07-01 | — | — | US | disclosed |
| US-7691967-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691967-B2 | Smart pro-drugs of serine protease inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | HTR2C 3121/4885HTR2B 1386/4885ALDH1A1 3107/4885 |
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | HTR2C 3121/4885HTR2B 1386/4885ALDH1A1 3107/4885 |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | HTR2C 3121/4885HTR2B 1386/4885ALDH1A1 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.